Hepatitis C virus and Human Immunodeficiency Virus coinfection among attendants of Voluntary Counseling and Testing Centre and HIV follow up clinics in Mekelle Hospital

Department of Microbiology, Immunology and Parasitology, School of Medicine, Addis Ababa University, Ethiopia.
Pan African Medical Journal 03/2013; 14:107. DOI: 10.11604/pamj.2013.14.107.2302
Source: PubMed


Hepatitis C virus remains a large health care burden to the world. HIV and HCV coinfection is major global health concern worldwide. However, there is limited information on the prevalence of HCV/HIV co-infection in Ethiopia. The aim of the study was to assess the magnitude of HIV/HCV coinfection and the potential risk factors in attendants of voluntary counseling and testing centre and HIV follow up clinics of Mekelle hospital.
A cross sectional seroprevalence survey of HCV infection was carried out on 300 HIV negative and positive subjects attending voluntary counseling and testing (VCT) center and HIV follow up clinics of Mekelle hospital, Ethiopia from December 2010-February 2011. Serum samples were tested for anti-HCV antibodies using immunochromatographic test.
Of the 300 study participants, 126(42%) were HIV negative and 174(58%) HIV seropositive from VCT and HIV follow up clinics, respectively. The overall anti-HCV prevalence was 18(6.0%). There were no significant differences in HCV seroprevalence among the different categories of age and sex (p> 0.05). Of the 174 persons with HIV, 16 (9.2%) cases had antibodies to HCV, where as among 126 HIV negative subjects 2 (1.58%) were HCV seropositive (p= 0.006, OR= 6.28, 95% CI= 1.42-27.82).
Accordingly, there was a significant difference in sero-positivity of HCV between HIV positive and HIV negative participants. No apparent risk factor that caused HCV infection was inferred from this study.

Download full-text


Available from: Solomon Gebre-Selassie, Jan 28, 2014
  • Source
    • "In a study of 378 HIV positive individuals in Nairobi, Kenya 6% were co-infected with HBV while 1% was co-infected with HCV [18]. While in a cohort of 138 HIV positive patients in Ghana HBV and HCV co-infection respectively were 13% and 3.6% [19] and another cohort of 126 HIV positive individuals in Mekelle, Ethiopia 9.2% were co-infected with HCV [20]. These prevalence values are higher than our observation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Highly active antiretroviral therapy (HAART) has improved survival of human immunodeficiency virus (HIV) patients. Concurrent morbidities from liver diseases among these patients have also been observed due to co-infection with hepatitis B and C viruses (HBV and HCV). HAART reduces liver-associated morbidities and mortalities in such patients. Unfortunately free testing of HBV and HCV are not provided alongside free HIV testing and treatment in Nigeria. We assessed the seroprevalence of HBV and HCV among HIV patients presenting for treatment in our center. This prospective study of adult patients with HIV/AIDS assessed the seroprevalence of HBV and HCV co-infection using a 19-item questionnaire and collection of 2ml venous blood for hepatitis B surface antigens (HBsAg) and anti-HCV antibodies. All previously diagnosed HIV patients of the unit were excluded from the study. Of the 404 patients, 69.2% were females while 30.8% were males. Married participants were 59.6%, 25.3% were single and 15% were previously married. A large proportion (69%) of patients were farmers, artisans and traders. Most had some formal education; secondary (55.3%), primary 27.3%, tertiary 13.8%. HBsAg positive participants were 9 (2.2%) while 3 (0.7%) were positive for HCV. No participant had triple infection of HIV/HBV/HCV. Seroprevalence of HBV and HCV is low among HIV patients in Orlu. However there is a need for HBV and HCV testing of all HIV positive patients to reduce morbidities and mortalities from liver diseases.
    Full-text · Article · Sep 2013 · Pan African Medical Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction The national prevalence of hepatitis C virus (HCV) is not known in Burundi. Studies carried out in specific populations found various rates. There is no nationwide study made in the country. Aim To determine the prevalence of anti-HCV antibodies in Burundi based on a nationwide survey. Methods During a nationwide survey of HIV prevalence in 2002, conducted by the CEFORMI in CHU Kamenge, two to four ml of serum and plasma had been extracted from each sample and stored under −20°C for an ulterior use. We recuperated and analyzed them. Results A total of 5569 persons have been enrolled. 2660 (47,8%) were males and 2909 (52,2%) females. The mean age was 31±15 years with a median of 28 years. The global prevalence of HVC antibodies was 8,2%. It was 8,3% among males and 8,1% among females. According to strata, the prevalence was 10% in urban area, 9,1% in semi-urban area and 7,4% in rural area. The co-infection with HIV was 1,3% in urban area, 0,8% in semi-urban area and 0,1% in rural area. Conclusion The prevalence of anti-HCV antibodies is estimated to 8,2% in Burundi. It is one of the highest rates in Africa.
    No preview · Article · Mar 2014 · Journal Africain d?Hépato-Gastroentérologie
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) are blood-borne viruses with potentially shared routes of transmission. In high-income settings, the impact of antiretroviral therapy (ART) on survival has unmasked chronic liver disease from viral hepatitis B or hepatitis C as a leading cause of morbidity and mortality in individuals with HIV infection. It is now feared that progressive liver disease may threaten the success of ART programmes in developing countries, where HCV or HBV testing and monitoring are not yet systematic among HIV-infected patients and ART use is generally blind to these co-infections. We set out to review recent data from Sub-Saharan Africa, in order to build a detailed and up-to-date picture of the epidemiology and emerging impact of HBV and HCV coinfection in countries at the heart of the HIV pandemic. There is a preponderance of HIV/HBV coinfection compared to HIV/HCV in this region, and significant caveats exist regarding the accuracy of published HCV seroprevalence surveys. Morbidity and mortality of coinfection is significant, and may be further enhanced in African populations due to the influence of host, viral and environmental factors. Careful scrutiny of the coinfection problem is vital to inform an approach to directing resources, planning public health initiatives, providing clinical care, and guiding future research.
    Full-text · Article · Sep 2014 · Journal of Clinical Virology
Show more